RA CAPITAL MANAGEMENT, L.P. purchased $194K of ARTV (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 21,654 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $8.96 ($8.94–$8.97, $0.19M total) across 2 trades over 2026-07-10 to 2026-07-13.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jul 14, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 14, 2026, 11:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bullish
medium confidence
Mentioned
$ARTV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBullishLow
01

Why it matters

The newest fact is the reported open-market purchase by RA Capital Management, L.P. (director and 10% owner) at an average price of $8.9609, totaling $194,039.82, with holdings after the transaction of 16,817,573 shares.

02

Market read

Traders may note mild sentiment support from insider accumulation, but there is no new fundamental catalyst in the filing.

03

What to watch

The purchase is indirect and there is no 10b5-1 plan disclosed; without context on prior buying/selling patterns, the signal strength is uncertain.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-07-14 after trades dated 2026-07-10 to 2026-07-13.

Background

The article is an SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics, Inc.

Company-level read

Ticker impact

$ARTVBullishMedium confidence
Context

RA Capital Management, a director and 10% owner, bought 21,654 Artiva Biotherapeutics shares in open-market trades at about $8.96.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by larger or repeated buying.

Evidence & confidence

The filing is a Form 4 open-market purchase by an insider/10% owner via indirect holdings, with no new guidance, trial, or deal disclosed. The disclosed size ($194k) is modest relative to typical market-moving thresholds.

Market effects

No clear sector read-through; this is company-specific insider buying with no disclosed program or regulatory change.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine (tax, liquidity planning, or pre-existing arrangements) and may not reflect a change in business outlook.

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure (ARTV).

  • RA Capital Management, L.P.

    Director and 10% owner who reported an indirect open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.